Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 14, 2021
Reporting Period: Event-based disclosure regarding a specific contract award.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, margins, debt, or liquidity). The primary financial metric disclosed is the estimated value of a new procurement contract.
- Contract Value: Estimated at $205 million.
- Product: InteliSwab COVID-19 Rapid Test for over-the-counter use.
- Contract Duration: October 2021 through September 2022.
- Scope: Supply to up to 25,000 sites throughout the United States.
Material Changes
The filing reports a material event: the award of a significant procurement contract by the Defense Logistics Agency (DLA). This represents a new revenue opportunity rather than a change in historical financial performance.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the contract award via a press release on September 20, 2021, incorporated as Exhibit 99.1.
Outlook: The contract is expected to generate revenue over the 12-month period from October 2021 to September 2022, subject to the terms of the agreement.
Risks and Contingencies: The filing explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report.
Investor Verification Checklist
- Verify the final execution and terms of the $205 million contract with the Defense Logistics Agency.
- Confirm the actual volume of tests delivered against the "up to 25,000 sites" estimate.
- Review the attached Press Release (Exhibit 99.1) for specific delivery schedules and payment terms.
- Monitor future filings for updates on revenue recognition related to this contract, as the Company does not commit to updating this specific 8-K.